Raleukin
Raleukin is an engineered recombinant IL-2 analogue designed to preferentially engage the intermediate-affinity IL-2Rbeta-gamma receptor on effector T cells and NK cells while reducing binding to the high-affinity IL-2Ralpha (CD25) receptor on immunosuppressive regulatory T cells. This selectivity improves the therapeutic index for immune stimulation without excessive Treg expansion.
Description
Scientific Overview: Raleukin is an engineered recombinant IL-2 analogue designed to preferentially engage the intermediate-affinity IL-2Rbeta-gamma receptor on effector T cells and NK cells while reducing binding to the high-affinity IL-2Ralpha (CD25) receptor on immunosuppressive regulatory T cells. This selectivity improves the therapeutic index for immune stimulation without excessive Treg expansion.
Mechanism of Action: IL-2 Receptor Agonist (recombinant IL-2 analogue)
Purity: ≥95% | Molecular Formula: Recombinant human IL-2 (cytokine)
For Research Use Only. Not intended for diagnostic, therapeutic, or clinical applications.
Additional information
| Effect | IL-2 Receptor Agonist (recombinant IL-2 analogue) |
|---|---|
| Purity | ≥95% |
| Molecular Formula | Recombinant human IL-2 (cytokine) |
| CAS Number | N/A (biologic) |
